Literature DB >> 32067685

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.

A Yver1, T Agatsuma2, J-C Soria3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 32067685     DOI： 10.1016/j.annonc.2019.11.019

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.

Authors:  James T Coates; Sheng Sun; Ignaty Leshchiner; Nayana Thimmiah; Elizabeth E Martin; Daniel McLoughlin; Brian P Danysh; Kara Slowik; Raquel A Jacobs; Kahn Rhrissorrakrai; Filippo Utro; Chaya Levovitz; Elyssa Denault; Charlotte S Walmsley; Avinash Kambadakone; James R Stone; Steven J Isakoff; Laxmi Parida; Dejan Juric; Gad Getz; Aditya Bardia; Leif W Ellisen
Journal:  Cancer Discov       Date:  2021-08-17       Impact factor: 39.397

2.  Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.

Authors:  Yingying Xu; Yakun Wang; Jifang Gong; Xiaotian Zhang; Zhi Peng; Xinan Sheng; Chenyu Mao; Qingxia Fan; Yuxian Bai; Yi Ba; Da Jiang; Fen Yang; Changsong Qi; Jian Li; Xicheng Wang; Jun Zhou; Ming Lu; Yanshuo Cao; Jiajia Yuan; Dan Liu; Zhenghang Wang; Jianmin Fang; Lin Shen
Journal:  Gastric Cancer       Date:  2021-05-04       Impact factor: 7.701

Review 3.  Antibody-drug conjugates: beyond current approvals and potential future strategies.

Authors:  Siddharth Menon; Sagun Parakh; Andrew M Scott; Hui K Gan
Journal:  Explor Target Antitumor Ther       Date:  2022-04-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.